AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32993794
Drug: BEZ235 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEZ235 (300 mg BID)
Trial: 32995919
Drug: Standard IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IV intermittent bolus paracetamol therapy (15-mg/kg doses as 1-h infusions every 6 h for 5 days)
Trial: 32995919
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV paracetamol infusion therapy (60-mg/kg/day continuously for 5 days)
Trial: 32995944
Drug: Pridopidine 1
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 1 mg
Trial: 32995944
Drug: Pridopidine doses
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine doses ranging from 22.5 to 90 mg
Trial: 32996064
Drug: Ceftolozane/tazobactam 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam 3 g (ceftolozane 2 g/tazobactam 1 g)
Trial: 32996064
Drug: Meropenem 1
RxNorm normalized name: meropenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem 1 g
Trial: 32996096
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI) 80 U subcutaneously every other day to week 4, then twice weekly to week 24
Trial: 32998963
Drug: Itacitinib (INCB039110),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itacitinib (INCB039110), a JAK1 inhibitor
Trial: 32998965
Drug: Alvocidib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvocidib (30 mg/m²) followed by 7+3 (Cytarabine 100 mg/m² + Daunorubicin)
Trial: 32998965
Drug: Alvocidib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvocidib (30 mg/m²)
Trial: 33000661
Drug: Crystalloid administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crystalloid administration within the preceding 24 hours
Trial: 33001549
Drug: Bilateral dorsolateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral dorsolateral prefrontal cortex (DLPFC) theta burst stimulation (TBS) treatment for 2 weeks
Trial: 33001967
Drug: SARS-CoV-2 antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 antibodies (detected via lateral flow immunoassay test)
Trial: 33002543
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) every 3 weeks for 4 doses followed by Nivolumab monotherapy (480 mg) every 4 weeks until progression or up to 1 year after consolidative thoracic radiation therapy (30 Gy in 10 fractions).
Trial: 33002543
Drug: Ipilimumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipilimumab (3 mg/kg) and Nivolumab (1 mg/kg) with thoracic radiation therapy after platinum chemotherapy.
Trial: 33002543
Drug: Ipilimumab and
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab and Nivolumab treatment.
Trial: 33002543
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in peripheral blood CD3+CD8+ from baseline to after first dose of IPI/NIVO.
Trial: 33003016
Drug: Vasopressor dose
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressor dose
Trial: 33004046
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion radiotherapy (CIRT) with a total irradiation dose of 48 Gy (RBE) delivered in twelve fractions; concurrent chemotherapy accepted if indicated.
Trial: 33004541
Drug: Chemotherapy/ICI combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/ICI combinations
Trial: 33004542
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg intravenous every 3 weeks + Bevacizumab 15 mg/kg intravenous every 3 weeks
Trial: 33004656
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic volume of 5 mL
Trial: 33004656
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic volume of 30-35 mL
Trial: 33004656
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic volume (various doses from 5 to 40 mL)
Trial: 33004691
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IGF1 treatment
Trial: 33007932
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment strategies according to local protocols in cardiac centers
Trial: 33007932
Drug: Invasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive therapy and antithrombotic therapy including patient-tailored strategies
Trial: 33008303
Drug: Chronic kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic kidney disease (CKD) defined as GFR < 60, < 45 or < 30 ml/min/1.73 m²
Trial: 33008303
Drug: Chronic kidney
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic kidney disease (CKD) defined as eGFR < 45 or 30 ml/min/1.73 m²
Trial: 33008401
Drug: New estrogen-free
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New estrogen-free contraceptive pill (4 mg drospirenone, 24/4 regimen)
Trial: 33008435
Drug: Medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication therapy for challenging behavior
Trial: 33008435
Drug: Non-medication approaches
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-medication approaches
Trial: 33008938
Drug: Breath volatile
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breath volatile organic compounds
Trial: 33010149
Drug: HCV direct-acting
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV direct-acting antiviral treatment
Trial: 33010149
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment scale-up
Trial: 33010231
Drug: ARI-0001 cells
RxNorm normalized name: OVIS ARIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARI-0001 cells (chimeric antigen receptor T cells targeting CD19)
Trial: 33010459
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg QD plus nivolumab 240 mg every 2 weeks
Trial: 33010459
Drug: Tivozanib 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivozanib 1.5 mg QD
Trial: 33010817
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.8 mg/kg (cap at 180 mg) and nivolumab at 3 mg/kg, both intravenously every 21 days for 8 cycles
Trial: 33010927
Drug: Intramuscular tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular tranexamic acid (TXA) 1 g i.v. loading dose followed by two 5 ml (0.5 g each) i.m. injections
Trial: 33010927
Drug: Intramuscular tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular tranexamic acid (TXA)
Trial: 33011782
Drug: Chemotherapy-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-only treatment (phase 3 trial)
Trial: 33011923
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec 100 units/mL, given once daily after switching from other basal insulins
Trial: 33012343
Drug: Cell therapy
RxNorm normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cell therapy (CD34)
Trial: 33012782
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg Q2W) + Gefitinib (250 mg QD)
Trial: 33012782
Drug: Durvalumab and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab and gefitinib in combination
Trial: 33013302
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks sound therapy using adjusted narrow band sound
Trial: 33014443
Drug: Standard bandage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bandage contact lens (PureVision B&L)
Trial: 33015088
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in well-nourished patients
Trial: 33015088
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in malnourished patients
Trial: 33015088
Drug: Chemotherapy-related toxicity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-related toxicity
Trial: 33015104
Drug: Vaginal Lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Lactoferrin administration
Trial: 33016100
Drug: Sacubitril/Valsartan (S/V)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/Valsartan (S/V) treatment
Trial: 33016805
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment for symptomatic PAD
Trial: 33017106
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy (10-day course)
Trial: 33017497
Drug: Ramucirumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab (8 mg/kg IV, day 1 every 2 weeks) plus FOLFOX4
Trial: 33020594
Drug: TAS-119 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-119 (200 mg BID, 4 days on/3 days off, 3 out of 4 weeks)
Trial: 33020594
Drug: TAS-119 (150,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-119 (150, 200, 250, 300 mg BID)
Trial: 33020924
Drug: DPYD-guided dose-individualization
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPYD-guided dose-individualization
Trial: 33021872
Drug: Anti-CD19 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD19 CAR T-cell therapy (FMC63-28Z)
Trial: 33022101
Drug: Dopamine agonist
RxNorm normalized name: Dopamine agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist dose reduction
Trial: 33022752
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of educational and environmental interventions
Trial: 33023948
Drug: XPO1 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XPO1 inhibitors (selinexor, eltanexor, KOS-2464) combined with melphalan
Trial: 33023948
Drug: Single-agent melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-agent melphalan
Trial: 33023948
Drug: XPO1 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XPO1 inhibitors (selinexor, eltanexor) with melphalan
Trial: 33023952
Drug: Neoadjuvant enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Neoadjuvant enzalutamide plus androgen deprivation therapy (ADT)
Trial: 35166065
Drug: Enasidenib 100
RxNorm normalized name: enasidenib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib 100 mg once daily
Trial: 33025213
Drug: Palbociclib (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palbociclib (125 mg/day for 3 weeks on, 1 week off)
Trial: 33025378
Drug: IgPro20 manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 manual push infusion at 0.5 mL/min
Trial: 33025378
Drug: IgPro20 manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 manual push infusion at 1.0 mL/min
Trial: 33025378
Drug: IgPro20 manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgPro20 manual push infusion at 2.0 mL/min
Trial: 33025481
Drug: Black carbon
RxNorm normalized name: black carbon, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black carbon dye tattooing of biopsied axillary node (2.0 ml median volume injected, range 0.2-4.2 ml)
Trial: 33025481
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NACT) group
Trial: 33025481
Drug: Timing between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing between dye injection and surgery
Trial: 33025482
Drug: Eribulin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin as first- or second-line therapy
Trial: 33025707
Drug: L-leucine 700
RxNorm normalized name: L-Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-leucine 700 mg/m
Trial: 33025716
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg erythromycin infused intravenously over 20 min
Trial: 33026753
Drug: Efinaconazole 10%
RxNorm normalized name: EFINACONAZOLE 10% SOLN,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole 10% topical solution, administered once daily for 48 weeks
Trial: 33026772
Drug: Halobetasol propionate
RxNorm normalized name: Halobetasol Propionate
DrugBank: Ulobetasol (DB00596)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halobetasol propionate 0.01%/Tazarotene 0.045% lotion (HP/TAZ)
Trial: 33027528
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with lymphoma- or AL-like regimens followed by transplantation
Trial: 33028169
Drug: Prolonged release
RxNorm normalized name: EYE DROPS, PROLONGED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged release budesonide granules (9 mg daily for 8 weeks)
Trial: 33028346
Drug: Short-course radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiation followed by 6 cycles of mFOLFOX6 plus avelumab (10 mg/kg) every 2 weeks for 6 cycles.
Trial: 33029135
Drug: 30 ml articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml articaine 2%
Trial: 33029135
Drug: 30 ml bupivacaine
RxNorm normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 ml bupivacaine 0.5%
Trial: 33030704
Drug: Teicoplanin (weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (weight-based dosing regimen)
Trial: 33031046
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Behavioral Activation, 50-minute weekly sessions for 4 weeks using a VR headset
Trial: 33031354
Drug: Family-Assisted Severe
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Assisted Severe Febrile Illness Therapy
Trial: 33031542
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of venetoclax plus ibrutinib for ≥12 months
Trial: 33031809
Drug: Cross-Linking treatment
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-Linking treatment for fungal keratitis
Trial: 38479192
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) ketamine infusions
Trial: 33031955
Drug: Tocilizumab 8
RxNorm normalized name: tocilizumab 80 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab 8 mg/kg (up to 800 mg) as one intravenous administration, with a second optional administration after 12 hours.
Trial: 33032328
Drug: Overall supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall supplement intake
Trial: 33032328
Drug: Overall medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall medication use
Trial: 33032571
Drug: Cardiovascular medication
RxNorm normalized name: CARDIOVASCULAR MEDICATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiovascular medication of ticagrelor
Trial: 33033101
Drug: Vedolizumab 150
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab 150 mg
Trial: 33033101
Drug: Vedolizumab 75
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab 75 mg
Trial: 33033101
Drug: Vedolizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vedolizumab (all doses)
Trial: 33046517
Drug: CC-90011
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-90011
Trial: 33034295
Drug: Intravital microscopy
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravital microscopy (IVM) during administration of vasopressors or fluid boluses
Trial: 33034839
Drug: Ribociclib (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib (350 mg/m2) administered following radiotherapy in 28-day cycles
Trial: 33035333
Drug: Axicabtagene ciloleucel
RxNorm normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axicabtagene ciloleucel (axi-cel), an anti-CD19 CAR T-cell therapy
Trial: 33037105
Drug: 250 mg/day
RxNorm normalized name: alpelisib 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg/day gefitinib (oral) and 2.0 mg/m² topotecan
Trial: 33037117
Drug: IT MEDI9197
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT MEDI9197 0.005-0.055 mg
Trial: 33037117
Drug: IT MEDI9197
RxNorm normalized name: IT-139
DrugBank: IT-139 (DB17145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IT MEDI9197 0.012 mg plus durvalumab 1500 mg
Trial: 33037135
Drug: BI 905711,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 905711, a novel tetravalent bispecific antibody targeting TRAILR2 and CDH17
Trial: 33038190
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg subcutaneously) once every 4 weeks during the treatment phase, with loading doses on days 8 and 15 of the first cycle.
Trial: 33038277
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy with nab-paclitaxel and gemcitabine
Trial: 33038286
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg daily
Trial: 33038286
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg daily
Trial: 33038286
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg daily (patients meeting criteria for dose reduction)
Trial: 33038286
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg daily (patients meeting criteria for dose reduction)
Trial: 33038346
Drug: Candidate anxiolytics
RxNorm normalized name: ANXIOLYTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate anxiolytics tested in human models of anxiety using anxiety-potentiated startle.
Trial: 33039599
Drug: Brigatinib 90
RxNorm normalized name: brigatinib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib 90 mg daily for 7 days, then escalated to 180 mg daily
Trial: 33039812
Drug: Intraperitoneal oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intraperitoneal oxaliplatin delivered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) at a dose of 90 mg/m
Trial: 33040013
Drug: VitalScan MCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VitalScan MCG (Creavo Medical Technologies, UK)
Trial: 33040383
Drug: Omnipod Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omnipod Insulin Management System
Trial: 33042202
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) and aromatase inhibitor therapy (AIT)
Trial: 33042579
Drug: IV infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of 4 mg/kg tocilizumab (TCZ)
Trial: 33042579
Drug: IV infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusions of 8 mg/kg tocilizumab (TCZ)
Trial: 33043164
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg, up to 800 mg, single shot)